arrow
J

John J. Powers

Moffitt Cancer Center
H指数:29
被引数:3,427

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting S100A9-mediated inflammation: A novel therapeutic approach for CLL

靶向S100A9介导的炎症:慢性淋巴细胞白血病的一种新型治疗策略

2025-07-290
OAAI
Correction: An FGFR-p53 developmental signaling axis drives salivary cancer progression

更正: FGFR-p53的发育信号轴驱动唾液癌进展

2025-06-200
PREAI
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model

在慢性淋巴细胞白血病中缓解T细胞线粒体功能障碍以增强CAR T细胞疗法:在免疫健全模型中的评估

2025-01-010
OA
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial
2024-11-091
PRE
Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers

用二聚体IgA靶向细胞内癌蛋白促进从细胞质中的排出和免疫介导的上皮癌控制

IMMUNITY
IF26.3
2023-11-0114
OA
Sezary syndrome originates from heavily mutated hematopoietic progenitors

Sezary综合征起源于严重突变的造血祖细胞

2023-09-183
OAAI
Spontaneous class-switched antibody responses at endometrial cancer tumor bed drives superior patients' outcome
2022-05-010
PRE
Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T-cells
2022-05-010
OA
IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer
2022-03-0331
OA
TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures
IMMUNITY
IF26.3
2022-01-0188
OA
Plasma cell dependence on histone/protein deacetylase11 reveals a therapeutic target in multiple myeloma
2021-12-229
OA
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells (vol 9, 6136, 2019)
2019-10-106
OAAI